January 13 - 16, 2020

# 38TH ANNUAL HEALTHCARE CONFERENCE

San Francisco, California



Thirty seven years ago, we launched Wall Street's premier investor conference focused exclusively on companies defining the healthcare industry. Today, the J.P. Morgan Healthcare Conference continues our tradition of hosting the largest and most informative healthcare investment symposium in the industry. In 2020, we expect more than 400 companies, both public and private, to deliver presentations to more than 8,000 attendees.

To request an invitation, please contact your J.P. Morgan representative.

All J.P. Morgan conferences are by invitation only. Invitations are non-transferable.

#### https://jpmorgan.metameetings.net/events/hc20/general\_signin

# THURSDAY, JANUARY 16 CONFERENCE AGENDA

	Colonial Room Breakout: Georgian Room	California West Breakout: Olympic Room	California East Breakout: Yorkshire Room	Elizabethan A Breakout: Sussex Room	Elizabethan B Breakout: Kent Room	Elizabethan C Breakout: Victorian Room	Elizabethan D Private Companie
7:00 AM	Registration: Presenting Company — Colonnade, Lobby Level   Non-Presenting Company — Tower Salon, Lobby Level Breaklast — Italian Foyer, Mezzanine Level						
:30 AM	Five Prime Therapeutics	HMS Holdings Corp.	Lexicon Pharmaceuticals, Inc.	Endologix	Rigel Pharmaceuticals, Inc.	Idera Pharmaceuticals	
:00 AM	NVIDIA Corporation	Gritstone Oncology	Jounce Therapeutics Inc	TransEnterix, Inc.	AngioDynamics, Inc.	TG Therapeutics Inc	VillageMD
:30 AM	Sangamo Therapeutics	Inogen Inc	Halozyme Therapeutics, Inc.	Axcella Health Inc.	Oxford Immunotec	Atara Biotherapeutics	
:00 AM	Owens & Minor, Inc.	CymaBay Therapeutics	Insmed	Infinity Pharmaceuticals, Inc.	Molecular Partners AG	Mersana Therapeutics	Havea
:30 AM	Acorda	ImmunoGen, Inc.	ZIOPHARM Oncology	Atricure	AMAG Pharmaceuticals, Inc.	InflaRx N.V.	CardioNxT
):00 AM	Veeva Systems, Inc.	NextCure	Arena Pharmaceuticals, Inc.	Kura	Medacta Group SA	Vectura Group plc	
D:30 AM	Agile	AdaptHealth	Galapagos NV	Axogen Inc	Biocartis	Natus	
1:00 AM		Novavax Inc.	Karuna Therapeutics	Misonix	Evotec	TCR2	
1:30 AM			ConforMIS, Inc.	Clearside Biomedical Inc	Iveric	Mithra	
	Conference Conclusion						

<sup>\*\*\*</sup>To-go lunches available beginning 11:00 am, Italian Foyer.

 $\label{prop:prop:section} \mbox{Agenda last updated 1/2/2020. Please check monitors located around the conference for agenda changes.}$ 

### GALAPAGOS NV

Presenting Thursday, January 16, 2020 at 10:30 AM

Room Analyst

California East



James Quigley

Description

Galapagos (Euronext & NASDAQ: GLPG) is a clinical-stage biotechnology company specialized in the discovery and development of small molecule medicines with novel modes of action. Our pipeline comprises Phase 3, 2, 1 studies, pre-clinical studies and discovery programs in inflammation, fibrosis and other indications. We seek to develop a robust portfolio of clinical-stage breakthrough therapies that have the potential to revolutionize existing treatment paradigms. Our ambition is to become a leading global biopharmaceutical company, focused on the discovery, development and commercialization of innovative medicines that will improve people's lives.

Galapagos' mission is to develop first-in-class medicines based on the discovery of novel targets. Using human primary cells and patient cells, the company discovers which proteins ('targets') play a key role in causing diseases such as rheumatoid arthritis, inflammatory bowel disease and fibrosis. Galapagos then aims to develop small molecules that inhibit these targets, restore the balance and thereby positively influence the course of the disease. This approach addresses the disease rather than just treating the symptoms. Galapagos' aim is to make a lasting positive contribution to society through discovery of breakthrough therapies for diseases with large unmet medical need.

Website www.glpg.com ☑ Bloomberg Ticker GLPG:NA ☑

#### Featuring

Speaker



**Bart Filius** 

COO/CFO, Galapagos NV

Sessions Galapagos NV

Technical Support